Recent 8-K filings for ENVB

• May 29, 2026, 4:13 PM ET other material materiality 0.65 neutral item 5.02item 5.07item 9.01

  Enveric shareholders approve reverse stock split, reject increase in authorized shares

  Reverse stock split (1:5 to 1:15) approved: 793,344 for, 190,175 against, 8,309 abstentions.

• May 15, 2026, 8:00 AM ET earnings materiality 0.70 positive item 2.02item 9.01

  Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M

  Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.

• April 30, 2026, 7:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  Enveric corrects proxy error: reverse split ratio range is 1-for-5 to 1-for-15, not 1-for-50

  Corrected reverse split range from erroneously stated 1-for-50 to correct 1-for-15 in proxy statement.

• April 20, 2026, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×3

  Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds

  Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised.

• March 27, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND

  Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.

• February 6, 2026, 6:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  Enveric Biosciences registers additional $1.346M in shares under ATM facility

  Filed prospectus supplement to register additional $1,346,000 of common stock under ATM agreement dated April 9, 2025.

• January 28, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Enveric Biosciences raises ~$1.5M in registered direct offering with warrants

  Sold 328,802 shares at $4.41 per share in a registered direct offering, gross proceeds ~$1.5M.

• January 9, 2026, 6:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  Enveric Biosciences releases investor presentation; no key figures disclosed in filing

  Investor presentation furnished on Jan 9, 2026, for use with investors, analysts, and partners.

• December 12, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Enveric Biosciences raises $3.1M via warrant exercise inducement at $7.05 per share

  Gross proceeds of ~$3.1M from cash exercise of 426,390 existing warrants at reduced price of $7.05/sh.

• December 11, 2025, 6:59 PM ET other material materiality 0.80 negative item 5.07item 9.01

  Enveric shareholders approve 50x increase in authorized shares and reverse split authority

  Approved increase in authorized common shares from 100M to 5B (50x) at board discretion.

• November 14, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026

  Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.

• November 14, 2025, 6:59 PM ET regulatory materiality 0.55 positive item 8.01

  Enveric regains Nasdaq minimum bid price compliance; delisting risk removed

  Received Nasdaq letter on Nov 12, 2025 confirming compliance with Listing Rule 5550(a)(2).

• October 23, 2025, 7:59 PM ET other material materiality 0.85 negative item 3.01item 3.03item 5.03item 8.01item 9.01 ◈ Listing & Compliance Notices◈ Governance Changes

  Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency

  Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.

• September 18, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 3.02item 9.01

  Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants

  Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.

• September 2, 2025, 7:59 PM ET other material materiality 0.30 positive item 7.01item 8.01item 9.01

  Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026

  Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.

• August 29, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement

  Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.

• August 29, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Enveric Biosciences files 8-K for investor presentation; no specific facts in filing

  Management will release a Q3 2025 investor presentation on the company's website on or about Aug 29, 2025.

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026

  Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.

• June 3, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07item 9.01

  Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting

  Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.

• May 14, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline

  Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.

• April 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01item 9.01

  Enveric Biosciences dismisses Marcum LLP, engages CBIZ CPAs as new auditor effective April 14

  Marcum LLP dismissed as independent auditor; CBIZ CPAs P.C. engaged effective April 14, 2025 for FY 2025.

• March 31, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M

  Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.

• March 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Enveric Biosciences regains Nasdaq bid price compliance

  Received notice from Nasdaq on March 4, 2025 that it complied with Listing Rule 5550(a)(2).

• February 26, 2025, 6:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  Enveric Biosciences files 8-K to announce investor presentation; no specifics provided

  Filing reports availability of an investor presentation on company website as of Feb 26, 2025.

• February 3, 2025, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 8.01item 9.01

  Enveric Biosciences closes ~$5M public offering of stock and warrants

  Gross proceeds ~$5M, net ~$4.3M from sale of 1.67M shares/pre-funded, Series A & B warrants at $3.00/unit.

• January 27, 2025, 6:59 PM ET other material materiality 0.25 neutral item 5.03item 9.01

  Enveric corrects reverse stock split effective date to January 29, 2025

  Reverse stock split of 1-for-15 will begin trading on Nasdaq Capital Market on January 29, 2025 (previously January 27).

• January 21, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 5.07item 9.01

  Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025

  Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.

• January 3, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Enveric Biosciences furnishes Q1 2025 investor presentation; content not detailed in filing

  Presentation posted on company website on January 3, 2025.

• November 22, 2024, 6:59 PM ET regulatory materiality 0.80 negative item 3.01

  Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure

  Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.

• November 14, 2024, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003

  Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.

• November 12, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties

  Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.

• August 22, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Enveric Biosciences files 8-K to announce investor presentation; no specific financial details provided

  Filing under Item 7.01 furnishes investor presentation (Exhibit 99.1) released on website on August 22, 2024 at 8:00 AM ET.

• August 12, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate

  Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.

• July 15, 2024, 7:59 PM ET other material materiality 0.55 positive item 1.01item 8.01item 9.01

  Enveric licenses radiation dermatitis product to Aries; eligible for up to $61M in milestones

  Akos (Enveric sub) grants Aries exclusive worldwide license for patented radiation dermatitis topical.

• May 29, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Enveric Biosciences shareholders elect all six director nominees and approve say-on-pay at 2024 annual meeting

  All six director nominees elected; Michael D. Webb received 767,013 for, 107,751 withheld.

• May 23, 2024, 7:59 PM ET regulatory materiality 0.50 neutral item 3.01

  Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains

  Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.

• May 17, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00

  Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.

• May 15, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets

  Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.

• May 3, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01 ◈ Material Agreements

  Enveric issues 458K shares at $0.94 to waive equity line restriction; no proceeds

  Issued 458,000 shares to institutional investors at $0.94 per share in registered direct offering.

• March 28, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.08

  Enveric sets May 28, 2024 Annual Meeting; stockholder proposal deadline April 8, 2024

  Annual Meeting scheduled for May 28, 2024, more than 30 days after 2023 meeting held Nov 2, 2023.

• March 26, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Enveric Biosciences reports Q4 2023 net loss of $3.44M; selects EB-003, signs out-licensing term sheets

  Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.

• March 19, 2024, 7:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  Enveric signs non-binding term sheets for out-licensing joint disease compounds; up to $82M in milestones

  Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.57 · Most common event other_material

8 positive 6 negative 28 neutral

source · ENVB on sec.gov